Deferasirox

A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.

Also Known As:

Networked: 707 relevant articles (119 outcomes, 173 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Porter, John B: 28 articles (01/2019 - 10/2006)
2.	Habr, Dany: 25 articles (09/2015 - 06/2009)
3.	Cappellini, Maria Domenica: 24 articles (01/2022 - 05/2006)
4.	Kattamis, Antonis: 23 articles (01/2022 - 05/2006)
5.	Piga, Antonio: 22 articles (01/2021 - 06/2003)
6.	Taher, Ali T: 19 articles (10/2023 - 12/2009)
7.	Viprakasit, Vip: 19 articles (10/2023 - 03/2010)
8.	Origa, Raffaella: 16 articles (04/2022 - 07/2006)
9.	Forni, Gian Luca: 16 articles (01/2022 - 07/2006)
10.	Galanello, Renzo: 16 articles (11/2013 - 06/2003)

Related Diseases

1.	Iron Overload 01/01/2012 - "We report two patients who achieved a marked improvement of hematopoiesis with the use of deferasirox (DSX) for transfusional iron overload. " 12/01/2013 - "Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial." 05/01/2012 - "In conclusion, our data suggest that oral deferasirox treatment may be used as a safe and effective alternative method for reducing iron overload in alloHSCT recipients, whether combined with or without phlebotomy." 06/01/2010 - "Although the number of subjects is small, deferasirox may be a safe and effective alternative for allogeneic HCT survivors with iron overload who cannot undergo phlebotomy." 08/01/2018 - "Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study."
2.	beta-Thalassemia (Cooley's Anemia) 10/01/2016 - "The use of oral deferasirox significantly improved the quality of life of adolescents with β-thalassemia major. " 06/01/2012 - "Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major." 05/01/2006 - "A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older. " 01/01/2019 - "Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function." 01/01/2012 - "Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report."
3.	Thalassemia 09/01/2021 - "Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience." 08/01/2014 - "Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience." 01/01/2012 - "HRQOL improved following treatment with deferasirox, particularly among β-thalassemia patients. " 10/01/2011 - "Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years." 03/01/2011 - "Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia."
4.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 09/01/2012 - "This analysis suggests that deferasirox treatment for up to 1 year could lead to improvement in hematologic parameters in some patients with myelodysplastic syndromes." 06/10/2012 - "This 3-year, prospective, multicenter trial assessed the safety and efficacy of deferasirox in low- or intermediate-1-risk myelodysplastic syndrome (MDS). " 05/01/2024 - "Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study." 05/01/2019 - "Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes." 03/01/2016 - "The primary objective of this study was to evaluate the health-related quality of life (HRQOL) in lower-risk, transfusion-dependent patients with myelodysplastic syndromes (MDS) treated with deferasirox. "
5.	Anemia 12/01/2019 - "For patients with MDS, AA, and other rare anemias, the AEs observed in this 3-year surveillance study with deferasirox were mostly mild or moderate. " 01/01/2022 - "Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes." 04/25/2018 - "However, it is not clear whether deferasirox may contribute to revert transfusion-dependent anemia. " 01/01/2015 - "Results confirm deferasirox efficacy in patients with rare anemias, including a Japanese subpopulation. " 01/01/2013 - "Here, we describe the case of a 73-year-old man affected by PMF and severe transfusion-dependent anemia who experienced a dramatic erythroid response after being treated with deferasirox to prevent IOL. "

Related Drugs and Biologics

1.	Iron
2.	Chelating Agents
3.	Deferoxamine (Desferal)
4.	Deferasirox
5.	Deferiprone
6.	Ferritins (Ferritin)
7.	liposomal amphotericin B
8.	Tablets
9.	Isoflurophate (DFP)
10.	Iron Chelating Agents

Related Therapies and Procedures

1.	Therapeutics
2.	Chelation Therapy (Therapy, Chelation)
3.	Blood Transfusion (Blood Transfusions)
4.	Stem Cell Transplantation
5.	Transplantation